SG172181A1 - Derivatives of 6-cycloamino-2,3-di-pyridinyl-imidazo[1,2-b]-pyridazine, preparation and therapeutic application thereof - Google Patents

Derivatives of 6-cycloamino-2,3-di-pyridinyl-imidazo[1,2-b]-pyridazine, preparation and therapeutic application thereof Download PDF

Info

Publication number: SG172181A1
Authority: SG; Singapore
Prior art keywords: group; alkyl; general formula; compound; groups
Prior art date: 2008-12-19

Application number

SG2011043833A

Other languages

English (en)

Inventor

Matthieu Barrague

Yulin Chiang

Pascal George

William A Metz

Frederic Puech

Mireille Sevrin

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-19

Filing date

2009-12-17

Publication date

2011-07-28

2009-12-17 Application filed by Sanofi Sa filed Critical Sanofi Sa

2011-07-28 Publication of SG172181A1 publication Critical patent/SG172181A1/en

Links

238000002360 preparation method Methods 0.000 title claims description 8
230000001225 therapeutic effect Effects 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims description 114
239000000203 mixture Substances 0.000 claims description 67
-1 cyclic amine Chemical class 0.000 claims description 34
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 29
125000001424 substituent group Chemical group 0.000 claims description 19
229910052799 carbon Inorganic materials 0.000 claims description 17
125000004432 carbon atom Chemical group C* 0.000 claims description 16
125000004122 cyclic group Chemical group 0.000 claims description 14
125000001153 fluoro group Chemical group F* 0.000 claims description 13
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
125000000217 alkyl group Chemical group 0.000 claims description 11
229910052731 fluorine Inorganic materials 0.000 claims description 11
238000005859 coupling reaction Methods 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
229910052736 halogen Inorganic materials 0.000 claims description 8
150000002367 halogens Chemical class 0.000 claims description 8
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 7
229910052757 nitrogen Inorganic materials 0.000 claims description 7
125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
150000003222 pyridines Chemical class 0.000 claims description 7
208000019116 sleep disease Diseases 0.000 claims description 7
208000020401 Depressive disease Diseases 0.000 claims description 6
230000008878 coupling Effects 0.000 claims description 6
238000010168 coupling process Methods 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
125000004430 oxygen atom Chemical group O* 0.000 claims description 6
125000004076 pyridyl group Chemical group 0.000 claims description 6
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
125000003118 aryl group Chemical group 0.000 claims description 5
229910052794 bromium Inorganic materials 0.000 claims description 5
239000011737 fluorine Substances 0.000 claims description 5
125000005843 halogen group Chemical group 0.000 claims description 5
238000006192 iodination reaction Methods 0.000 claims description 5
229910052740 iodine Inorganic materials 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 4
125000001626 borono group Chemical group [H]OB([*])O[H] 0.000 claims description 4
239000003054 catalyst Substances 0.000 claims description 4
125000000753 cycloalkyl group Chemical group 0.000 claims description 4
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 4
208000017164 Chronobiology disease Diseases 0.000 claims description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
150000001412 amines Chemical class 0.000 claims description 3
230000031709 bromination Effects 0.000 claims description 3
238000005893 bromination reaction Methods 0.000 claims description 3
208000027866 inflammatory disease Diseases 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
VRGCYEIGVVTZCC-UHFFFAOYSA-N 3,4,5,6-tetrachlorocyclohexa-3,5-diene-1,2-dione Chemical compound ClC1=C(Cl)C(=O)C(=O)C(Cl)=C1Cl VRGCYEIGVVTZCC-UHFFFAOYSA-N 0.000 claims description 2
208000019901 Anxiety disease Diseases 0.000 claims description 2
230000036506 anxiety Effects 0.000 claims description 2
230000004663 cell proliferation Effects 0.000 claims description 2
230000006951 hyperphosphorylation Effects 0.000 claims description 2
102000013498 tau Proteins Human genes 0.000 claims description 2
108010026424 tau Proteins Proteins 0.000 claims description 2
230000036651 mood Effects 0.000 claims 1
239000004576 sand Substances 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 79
239000000243 solution Substances 0.000 description 34
239000002904 solvent Substances 0.000 description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 21
239000000741 silica gel Substances 0.000 description 21
229910002027 silica gel Inorganic materials 0.000 description 21
UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
239000000047 product Substances 0.000 description 16
239000007787 solid Substances 0.000 description 16
239000000460 chlorine Substances 0.000 description 15
238000001914 filtration Methods 0.000 description 15
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 14
239000000843 powder Substances 0.000 description 14
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 14
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 13
206010028980 Neoplasm Diseases 0.000 description 13
235000011114 ammonium hydroxide Nutrition 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
239000012074 organic phase Substances 0.000 description 12
102100037398 Casein kinase I isoform epsilon Human genes 0.000 description 11
101001026376 Homo sapiens Casein kinase I isoform epsilon Proteins 0.000 description 11
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
IMUYJWVXEHHUHB-UHFFFAOYSA-N imidazo[1,2-b]pyridazine Chemical compound N1=CC=CC2=N[C]=CN21 IMUYJWVXEHHUHB-UHFFFAOYSA-N 0.000 description 11
238000000034 method Methods 0.000 description 11
229910052938 sodium sulfate Inorganic materials 0.000 description 11
235000011152 sodium sulphate Nutrition 0.000 description 11
238000012360 testing method Methods 0.000 description 10
108010047048 Casein Kinase Idelta Proteins 0.000 description 9
102100037402 Casein kinase I isoform delta Human genes 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
238000001816 cooling Methods 0.000 description 9
238000001035 drying Methods 0.000 description 9
QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 8
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 8
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
238000004587 chromatography analysis Methods 0.000 description 8
230000002060 circadian Effects 0.000 description 8
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
229910000024 caesium carbonate Inorganic materials 0.000 description 7
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000010438 heat treatment Methods 0.000 description 7
150000004942 imidazo[1,2-b]pyridazines Chemical class 0.000 description 7
239000003921 oil Substances 0.000 description 7
235000019198 oils Nutrition 0.000 description 7
239000012429 reaction media Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
238000011282 treatment Methods 0.000 description 7
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
102000011632 Caseins Human genes 0.000 description 6
108010076119 Caseins Proteins 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000005018 casein Substances 0.000 description 6
235000021240 caseins Nutrition 0.000 description 6
239000002609 medium Substances 0.000 description 6
239000002798 polar solvent Substances 0.000 description 6
150000004892 pyridazines Chemical class 0.000 description 6
239000012453 solvate Substances 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
108060001084 Luciferase Proteins 0.000 description 5
239000005089 Luciferase Substances 0.000 description 5
108010084455 Zeocin Proteins 0.000 description 5
239000002253 acid Substances 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
238000007872 degassing Methods 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 5
230000026731 phosphorylation Effects 0.000 description 5
238000006366 phosphorylation reaction Methods 0.000 description 5
238000010992 reflux Methods 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 5
235000019345 sodium thiosulphate Nutrition 0.000 description 5
238000003756 stirring Methods 0.000 description 5
239000000758 substrate Substances 0.000 description 5
PIPWSBOFSUJCCO-UHFFFAOYSA-N 2,2-dimethylpiperazine Chemical compound CC1(C)CNCCN1 PIPWSBOFSUJCCO-UHFFFAOYSA-N 0.000 description 4
HTIJVQJTGLWNLZ-UHFFFAOYSA-N 2-bromoimidazo[1,2-b]pyridazine Chemical class N1=CC=CC2=NC(Br)=CN21 HTIJVQJTGLWNLZ-UHFFFAOYSA-N 0.000 description 4
DTXVKPOKPFWSFF-UHFFFAOYSA-N 3(S)-hydroxy-13-cis-eicosenoyl-CoA Chemical compound NC1=CC=C(Cl)N=N1 DTXVKPOKPFWSFF-UHFFFAOYSA-N 0.000 description 4
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
208000019022 Mood disease Diseases 0.000 description 4
229910021529 ammonia Inorganic materials 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
150000001721 carbon Chemical group 0.000 description 4
210000002950 fibroblast Anatomy 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
238000004949 mass spectrometry Methods 0.000 description 4
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
PWXQCAAXMHCNGQ-UHFFFAOYSA-N 6-chloro-2-pyridin-4-ylimidazo[1,2-b]pyridazine Chemical compound C=1N2N=C(Cl)C=CC2=NC=1C1=CC=NC=C1 PWXQCAAXMHCNGQ-UHFFFAOYSA-N 0.000 description 3
102000005403 Casein Kinases Human genes 0.000 description 3
108010031425 Casein Kinases Proteins 0.000 description 3
101710118321 Casein kinase I isoform alpha Proteins 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
239000006145 Eagle's minimal essential medium Substances 0.000 description 3
101000994700 Homo sapiens Casein kinase I isoform alpha Proteins 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
238000003556 assay Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
230000026045 iodination Effects 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
UFYBTLOLWSABAU-UHFFFAOYSA-N (2-methylpyridin-4-yl)boronic acid Chemical compound CC1=CC(B(O)O)=CC=N1 UFYBTLOLWSABAU-UHFFFAOYSA-N 0.000 description 2
RGALBQILADNMKA-UHFFFAOYSA-N 2-bromo-1-pyridin-4-ylethanone;hydron;bromide Chemical compound Br.BrCC(=O)C1=CC=NC=C1 RGALBQILADNMKA-UHFFFAOYSA-N 0.000 description 2
XOQGZCNFTXZKAW-UHFFFAOYSA-N 2-bromo-3-iodo-6-(4-propan-2-ylpiperazin-1-yl)imidazo[1,2-b]pyridazine Chemical compound C1CN(C(C)C)CCN1C1=NN2C(I)=C(Br)N=C2C=C1 XOQGZCNFTXZKAW-UHFFFAOYSA-N 0.000 description 2
VQTWPMTVJWLTBE-UHFFFAOYSA-N 2-bromo-3-iodoimidazo[1,2-b]pyridazine Chemical class C1=CC=NN2C(I)=C(Br)N=C21 VQTWPMTVJWLTBE-UHFFFAOYSA-N 0.000 description 2
HRADVHZVMOMEPU-UHFFFAOYSA-N 3-iodopyrrolidine-2,5-dione Chemical compound IC1CC(=O)NC1=O HRADVHZVMOMEPU-UHFFFAOYSA-N 0.000 description 2
JVTKTZKSPATBCI-UHFFFAOYSA-N 3-pyridin-4-ylimidazo[1,2-b]pyridazine Chemical class C=1N=C2C=CC=NN2C=1C1=CC=NC=C1 JVTKTZKSPATBCI-UHFFFAOYSA-N 0.000 description 2
MLJMMEDENNTXCR-UHFFFAOYSA-N 6-(3,3-dimethylpiperazin-1-yl)-2-pyridin-4-ylimidazo[1,2-b]pyridazine Chemical compound C1CNC(C)(C)CN1C1=NN2C=C(C=3C=CN=CC=3)N=C2C=C1 MLJMMEDENNTXCR-UHFFFAOYSA-N 0.000 description 2
HSAHCMOZFNSMLH-UHFFFAOYSA-N 6-chloro-4-methylpyridazin-3-amine Chemical compound CC1=CC(Cl)=NN=C1N HSAHCMOZFNSMLH-UHFFFAOYSA-N 0.000 description 2
UWDLNRUFHRYMSE-UHFFFAOYSA-N 6-chloro-5-methylpyridazin-3-amine Chemical compound CC1=CC(N)=NN=C1Cl UWDLNRUFHRYMSE-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
208000020925 Bipolar disease Diseases 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
206010013980 Dyssomnias Diseases 0.000 description 2
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
235000019502 Orange oil Nutrition 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
JFIKAVQFXXOTMK-UHFFFAOYSA-N [Br-].NC1=C(C=C(N=[N+]1CC(=O)OCC)Cl)C Chemical compound [Br-].NC1=C(C=C(N=[N+]1CC(=O)OCC)Cl)C JFIKAVQFXXOTMK-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
VQYOKDLEFVOVEV-UHFFFAOYSA-L bis(2,6-diphenylphenoxy)-methylalumane Chemical compound [Al+2]C.[O-]C1=C(C=2C=CC=CC=2)C=CC=C1C1=CC=CC=C1.[O-]C1=C(C=2C=CC=CC=2)C=CC=C1C1=CC=CC=C1 VQYOKDLEFVOVEV-UHFFFAOYSA-L 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
239000010949 copper Substances 0.000 description 2
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 2
230000006806 disease prevention Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
DDIMQYUEHQSFBR-UHFFFAOYSA-N ethyl 2-(6-amino-3-chloropyridazin-1-ium-1-yl)acetate;bromide Chemical compound [Br-].CCOC(=O)C[N+]1=NC(Cl)=CC=C1N DDIMQYUEHQSFBR-UHFFFAOYSA-N 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
239000011630 iodine Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
208000024714 major depressive disease Diseases 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
208000007538 neurilemmoma Diseases 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000010502 orange oil Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
238000000746 purification Methods 0.000 description 2
LETVJWLLIMJADE-UHFFFAOYSA-N pyridazin-3-amine Chemical class NC1=CC=CN=N1 LETVJWLLIMJADE-UHFFFAOYSA-N 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
MNMVLOTUNPRWMU-UHFFFAOYSA-N 1,2-diazacycloundecane Chemical compound C1CCCCNNCCCC1 MNMVLOTUNPRWMU-UHFFFAOYSA-N 0.000 description 1
YMANQWHUUFJQOW-UHFFFAOYSA-N 1,2-diazaspiro[4.5]decane Chemical compound N1NCCC11CCCCC1 YMANQWHUUFJQOW-UHFFFAOYSA-N 0.000 description 1
FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
UUAVYXKRUSVCDJ-UHFFFAOYSA-N 1-cycloheptylazepane Chemical compound C1CCCCCC1N1CCCCCC1 UUAVYXKRUSVCDJ-UHFFFAOYSA-N 0.000 description 1
LLSRLLPHUVVLQJ-UHFFFAOYSA-N 1-cycloheptyldiazepane Chemical compound C1CCCCCC1N1NCCCCC1 LLSRLLPHUVVLQJ-UHFFFAOYSA-N 0.000 description 1
ULFNAOHBWGRYLW-UHFFFAOYSA-N 1-cyclononylazonane Chemical compound C1CCCCCCCC1N1CCCCCCCC1 ULFNAOHBWGRYLW-UHFFFAOYSA-N 0.000 description 1
PPNCOQHHSGMKGI-UHFFFAOYSA-N 1-cyclononyldiazonane Chemical compound C1CCCCCCCC1N1NCCCCCCC1 PPNCOQHHSGMKGI-UHFFFAOYSA-N 0.000 description 1
NFDXQGNDWIPXQL-UHFFFAOYSA-N 1-cyclooctyldiazocane Chemical compound C1CCCCCCC1N1NCCCCCC1 NFDXQGNDWIPXQL-UHFFFAOYSA-N 0.000 description 1
XLKPEAFVZSNDOE-UHFFFAOYSA-N 1-methylpyridazin-1-ium Chemical compound C[N+]1=CC=CC=N1 XLKPEAFVZSNDOE-UHFFFAOYSA-N 0.000 description 1
WHMHDUZYTJUDOC-UHFFFAOYSA-N 2,3-dipyridin-4-yl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)imidazo[1,2-b]pyridazine Chemical compound C1CCCN1C1CCN(C2=NN3C(C=4C=CN=CC=4)=C(N=C3C=C2)C=2C=CN=CC=2)CC1 WHMHDUZYTJUDOC-UHFFFAOYSA-N 0.000 description 1
IEVFOHWZMUNADC-UHFFFAOYSA-N 2,6-dibromo-7-methylimidazo[1,2-b]pyridazine Chemical compound N1=C(Br)C(C)=CC2=NC(Br)=CN21 IEVFOHWZMUNADC-UHFFFAOYSA-N 0.000 description 1
YBDFBJRBBRJQLY-UHFFFAOYSA-N 2,6-dibromo-8-methylimidazo[1,2-b]pyridazine Chemical compound CC1=CC(Br)=NN2C=C(Br)N=C12 YBDFBJRBBRJQLY-UHFFFAOYSA-N 0.000 description 1
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
ZGVVOWOQCVGIML-UHFFFAOYSA-N 2-bromo-6-(4-propan-2-ylpiperazin-1-yl)imidazo[1,2-b]pyridazine Chemical compound C1CN(C(C)C)CCN1C1=NN2C=C(Br)N=C2C=C1 ZGVVOWOQCVGIML-UHFFFAOYSA-N 0.000 description 1
LOFHUGHLLMXJPP-UHFFFAOYSA-N 2-bromo-6-chloro-8-methylimidazo[1,2-b]pyridazine Chemical compound CC1=CC(Cl)=NN2C=C(Br)N=C12 LOFHUGHLLMXJPP-UHFFFAOYSA-N 0.000 description 1
IEFGTBVANORJCW-UHFFFAOYSA-N 2-bromo-6-chloroimidazo[1,2-b]pyridazine Chemical compound N1=C(Cl)C=CC2=NC(Br)=CN21 IEFGTBVANORJCW-UHFFFAOYSA-N 0.000 description 1
ATTXXSOXZICWQJ-UHFFFAOYSA-N 2-iodoimidazo[1,2-b]pyridazine Chemical class N1=CC=CC2=NC(I)=CN21 ATTXXSOXZICWQJ-UHFFFAOYSA-N 0.000 description 1
DPFGGMREMMRJSP-UHFFFAOYSA-N 6-(3,3-dimethylpiperazin-1-yl)-2,3-dipyridin-3-ylimidazo[1,2-b]pyridazine Chemical compound C1CNC(C)(C)CN1C1=NN2C(C=3C=NC=CC=3)=C(C=3C=NC=CC=3)N=C2C=C1 DPFGGMREMMRJSP-UHFFFAOYSA-N 0.000 description 1
KUVYBNFNMWZLBC-UHFFFAOYSA-N 6-(3,3-dimethylpiperazin-1-yl)-3-iodo-2-pyridin-4-ylimidazo[1,2-b]pyridazine Chemical compound C1CNC(C)(C)CN1C1=NN2C(I)=C(C=3C=CN=CC=3)N=C2C=C1 KUVYBNFNMWZLBC-UHFFFAOYSA-N 0.000 description 1
FZPGZAYXQDATAX-UHFFFAOYSA-N 6-(3,3-dimethylpiperazin-1-yl)-3-iodo-8-methyl-2-pyridin-4-ylimidazo[1,2-b]pyridazine Chemical compound N1=C2C(C)=CC(N3CC(C)(C)NCC3)=NN2C(I)=C1C1=CC=NC=C1 FZPGZAYXQDATAX-UHFFFAOYSA-N 0.000 description 1
ARQYAESKVBOVQO-UHFFFAOYSA-N 6-(3,3-dimethylpiperazin-1-yl)-8-methyl-2-pyridin-4-ylimidazo[1,2-b]pyridazine Chemical compound N1=C2C(C)=CC(N3CC(C)(C)NCC3)=NN2C=C1C1=CC=NC=C1 ARQYAESKVBOVQO-UHFFFAOYSA-N 0.000 description 1
GSBHZRAODFNQSC-UHFFFAOYSA-N 6-chloro-2-pyridin-3-ylimidazo[1,2-b]pyridazine Chemical compound C=1N2N=C(Cl)C=CC2=NC=1C1=CC=CN=C1 GSBHZRAODFNQSC-UHFFFAOYSA-N 0.000 description 1
PXNUADPMALTCFD-UHFFFAOYSA-N 6-chloro-3-(2-methylpyridin-4-yl)-2-pyridin-4-ylimidazo[1,2-b]pyridazine Chemical compound C1=NC(C)=CC(C=2N3N=C(Cl)C=CC3=NC=2C=2C=CN=CC=2)=C1 PXNUADPMALTCFD-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
229910014265 BrCl Inorganic materials 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
102100025878 C1q-related factor Human genes 0.000 description 1
101150047910 CSNK1D gene Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102000008122 Casein Kinase I Human genes 0.000 description 1
108010049812 Casein Kinase I Proteins 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
208000001456 Jet Lag Syndrome Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000003926 Myelitis Diseases 0.000 description 1
201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000006199 Parasomnias Diseases 0.000 description 1
101150003085 Pdcl gene Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
MXZNUGFCDVAXLG-CHWSQXEVSA-N [(2S)-1-[(2R)-3-methyl-2-(pyridine-4-carbonylamino)butanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@@H](NC(=O)c1ccncc1)C(=O)N1CCC[C@@H]1B(O)O MXZNUGFCDVAXLG-CHWSQXEVSA-N 0.000 description 1
VFHWCZMTMRVBAN-UHFFFAOYSA-N acetaldehyde hydrobromide Chemical compound Br.CC=O VFHWCZMTMRVBAN-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
LEKJTGQWLAUGQA-UHFFFAOYSA-N acetyl iodide Chemical class CC(I)=O LEKJTGQWLAUGQA-UHFFFAOYSA-N 0.000 description 1
208000024447 adrenal gland neoplasm Diseases 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
208000026900 bile duct neoplasm Diseases 0.000 description 1
208000027757 bipolar ll disease Diseases 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
CODNYICXDISAEA-UHFFFAOYSA-N bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052792 caesium Inorganic materials 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
230000027288 circadian rhythm Effects 0.000 description 1
229960003920 ***e Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940126208 compound 22 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229960000956 coumarin Drugs 0.000 description 1
235000001671 coumarin Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000006165 cyclic alkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000006735 deficit Effects 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
239000012973 diazabicyclooctane Substances 0.000 description 1
YORNAKOHJQKRLX-UHFFFAOYSA-N diazecane Chemical compound C1CCCCNNCCC1 YORNAKOHJQKRLX-UHFFFAOYSA-N 0.000 description 1
KJGHYQZXEYTDSW-UHFFFAOYSA-N diazocane Chemical compound C1CCCNNCC1 KJGHYQZXEYTDSW-UHFFFAOYSA-N 0.000 description 1
ZFYAUJTTYSSNEU-UHFFFAOYSA-N diazonane Chemical compound C1CCCNNCCC1 ZFYAUJTTYSSNEU-UHFFFAOYSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
208000024732 dysthymic disease Diseases 0.000 description 1
238000010828 elution Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
210000003372 endocrine gland Anatomy 0.000 description 1
201000003104 endogenous depression Diseases 0.000 description 1
229960004756 ethanol Drugs 0.000 description 1
VEIUVQORISMYBR-UHFFFAOYSA-N ethyl 2-(6-amino-3-chloro-4-methylpyridazin-1-ium-1-yl)acetate bromide Chemical compound [Br-].NC1=CC(=C(N=[N+]1CC(=O)OCC)Cl)C VEIUVQORISMYBR-UHFFFAOYSA-N 0.000 description 1
PKSFFPDHYYWQQX-UHFFFAOYSA-O ethyl 2-(6-amino-3-chloro-5-methylpyridazin-1-ium-1-yl)acetate Chemical compound CCOC(=O)C[N+]1=NC(Cl)=CC(C)=C1N PKSFFPDHYYWQQX-UHFFFAOYSA-O 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000005284 excitation Effects 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
210000005002 female reproductive tract Anatomy 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012909 foetal bovine serum Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
230000008570 general process Effects 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
206010020765 hypersomnia Diseases 0.000 description 1
210000003026 hypopharynx Anatomy 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
208000018937 joint inflammation Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000000021 kinase assay Methods 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
239000006210 lotion Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000005001 male reproductive tract Anatomy 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
240000004308 marijuana Species 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
201000005987 myeloid sarcoma Diseases 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
230000027405 negative regulation of phosphorylation Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
229910000069 nitrogen hydride Inorganic materials 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000007170 pathology Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000010363 phase shift Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
238000000711 polarimetry Methods 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-O pyridazin-1-ium Chemical compound C1=CC=[NH+]N=C1 PBMFSQRYOILNGV-UHFFFAOYSA-O 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000012216 screening Methods 0.000 description 1
208000012672 seasonal affective disease Diseases 0.000 description 1
150000003335 secondary amines Chemical group 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000001625 seminal vesicle Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
201000002314 small intestine cancer Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000003741 urothelium Anatomy 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
230000006439 vascular pathology Effects 0.000 description 1
239000013598 vector Substances 0.000 description 1
201000010653 vesiculitis Diseases 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Addiction (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG2011043833A 2008-12-19 2009-12-17 Derivatives of 6-cycloamino-2,3-di-pyridinyl-imidazo[1,2-b]-pyridazine, preparation and therapeutic application thereof SG172181A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR0807257A FR2940284B1 (fr)	2008-12-19	2008-12-19	Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
US13965208P	2008-12-22	2008-12-22
PCT/FR2009/052594 WO2010070238A1 (fr)	2008-12-19	2009-12-17	DÉRIVÉS DE 6-CYCLOAMINO-2,3-DI-PYRIDINYL-IMIDAZO[1,2-b]-PYRIDAZINE, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE

Publications (1)

Publication Number	Publication Date
SG172181A1 true SG172181A1 (en)	2011-07-28

Family

ID=40848284

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG2011043833A SG172181A1 (en)	2008-12-19	2009-12-17	Derivatives of 6-cycloamino-2,3-di-pyridinyl-imidazo[1,2-b]-pyridazine, preparation and therapeutic application thereof

Country Status (12)

Country	Link
EP (1)	EP2385946A1 (pt)
JP (1)	JP2012512853A (pt)
KR (1)	KR20110095964A (pt)
CN (1)	CN102325773A (pt)
AR (1)	AR074685A1 (pt)
AU (1)	AU2009329427A1 (pt)
BR (1)	BRPI0923182A2 (pt)
CA (1)	CA2747365A1 (pt)
FR (1)	FR2940284B1 (pt)
SG (1)	SG172181A1 (pt)
TW (1)	TW201028420A (pt)
WO (1)	WO2010070238A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9475817B2 (en)	2012-12-21	2016-10-25	Bristol-Myers Squibb Company	Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
CN105073751B (zh)	2012-12-21	2018-11-30	百时美施贵宝公司	作为酪蛋白激酶1δ/ε抑制剂的新的取代的咪唑
WO2015106158A1 (en)	2014-01-09	2015-07-16	Intra-Cellular Therapies, Inc.	Organic compounds
EP3157925B1 (en) *	2014-06-19	2019-12-18	Bristol-Myers Squibb Company	Imidazo-pyridazine derivatives as casein kinase 1 delta/epsilon inhibitors
AU2022367432A1 (en)	2021-10-14	2024-05-02	Incyte Corporation	Quinoline compounds as inhibitors of kras
WO2023147015A1 (en) *	2022-01-27	2023-08-03	The Broad Institute, Inc.	Substituted heterocyclic csnk1 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1989001333A1 (en) *	1987-08-07	1989-02-23	The Australian National University	IMIDAZO[1,2-b]PYRIDAZINES
US7151104B2 (en) *	2002-09-19	2006-12-19	Schering Corporation	Pyrazolopyridines as cyclin dependent kinase inhibitors
MXPA05006478A (es) *	2002-12-18	2005-09-08	Vertex Pharma	Triazolopiridazinas como inhibidores de proteinas cinasas.
US7402672B2 (en)	2003-12-11	2008-07-22	Aventis Pharmaceuticals Inc.	Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon
WO2005107760A1 (en) *	2004-04-30	2005-11-17	Irm Llc	Compounds and compositions as inducers of keratinocyte differentiation
JPWO2006070943A1 (ja) *	2004-12-28	2008-06-12	武田薬品工業株式会社	縮合イミダゾール化合物およびその用途
GB0515026D0 (en) *	2005-07-21	2005-08-31	Novartis Ag	Organic compounds
DE102005042742A1 (de) *	2005-09-02	2007-03-08	Schering Ag	Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
FR2918061B1 (fr) *	2007-06-28	2010-10-22	Sanofi Aventis	Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2918986B1 (fr) *	2007-07-19	2009-09-04	Sanofi Aventis Sa	Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique

2008
- 2008-12-19 FR FR0807257A patent/FR2940284B1/fr not_active Expired - Fee Related
2009
- 2009-12-16 AR ARP090104907A patent/AR074685A1/es unknown
- 2009-12-17 KR KR1020117016682A patent/KR20110095964A/ko not_active Application Discontinuation
- 2009-12-17 CN CN2009801571394A patent/CN102325773A/zh active Pending
- 2009-12-17 TW TW098143412A patent/TW201028420A/zh unknown
- 2009-12-17 JP JP2011541567A patent/JP2012512853A/ja not_active Withdrawn
- 2009-12-17 AU AU2009329427A patent/AU2009329427A1/en not_active Abandoned
- 2009-12-17 EP EP09805730A patent/EP2385946A1/fr not_active Withdrawn
- 2009-12-17 CA CA2747365A patent/CA2747365A1/fr not_active Abandoned
- 2009-12-17 SG SG2011043833A patent/SG172181A1/en unknown
- 2009-12-17 BR BRPI0923182A patent/BRPI0923182A2/pt not_active IP Right Cessation
- 2009-12-17 WO PCT/FR2009/052594 patent/WO2010070238A1/fr active Application Filing

Also Published As

Publication number	Publication date
CA2747365A1 (fr)	2010-06-24
BRPI0923182A2 (pt)	2019-09-24
WO2010070238A1 (fr)	2010-06-24
FR2940284A1 (fr)	2010-06-25
JP2012512853A (ja)	2012-06-07
EP2385946A1 (fr)	2011-11-16
AR074685A1 (es)	2011-02-02
FR2940284B1 (fr)	2011-02-18
TW201028420A (en)	2010-08-01
AU2009329427A1 (en)	2011-07-07
CN102325773A (zh)	2012-01-18
KR20110095964A (ko)	2011-08-25

Publication	Publication Date	Title
JP5537424B2 (ja)	2014-07-02	６−シクロアミノ−３−（ピリジン−４−イル）イミダゾ［１，２−ｂ］ピリダジン誘導体、これらの調製およびこれらの治療的使用
US9108971B2 (en)	2015-08-18	6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof
US20110312934A1 (en)	2011-12-22	2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine derivatives, preparation thereof, and therapeutic application thereof
SG172181A1 (en)	2011-07-28	Derivatives of 6-cycloamino-2,3-di-pyridinyl-imidazo[1,2-b]-pyridazine, preparation and therapeutic application thereof
SG172180A1 (en)	2011-07-28	Derivatives of 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine and 6-cycloamino-2-furanyl-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine, preparation and therapeutic application thereof
JP5677309B2 (ja)	2015-02-25	６−シクロアミノ−３−（１Ｈ−ピロロ［２，３−ｂ］ピリジン−４−イル）イミダゾ［１，２−ｂ］ピリダジン誘導体、この調製およびこの治療的使用
MX2011006627A (es)	2011-11-02	Derivados de 6-cicloamino-2,3-di-piridinil-imidazo[1,2-b]-piridazi na, su preparacion y su uso en terapeutica.